Initial agonist treatment of Parkinson disease - A critique

被引：60

作者：

Albin, RL

Frey, KA

机构：

[1] Univ Michigan, Ann Arbor VAMC, Dept Neurol, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Ann Arbor VAMC, Dept Radiol, Ann Arbor, MI 48109 USA

[3] Univ Michigan, Ann Arbor VAMC, Dept Geriatr Res Educ & Clin Ctr, Ann Arbor, MI 48109 USA

来源：

NEUROLOGY | 2003年 / 60卷 / 03期

关键词：

D O I：

10.1212/01.WNL.0000052681.28286.52

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.

引用

页码：390 / 394

页数：5

共 43 条

[1] Levodopa - Is toxicity a myth?
Agid, Y
[J]. NEUROLOGY, 1998, 50 (04) : 858 - 863
[2] Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
Ahlskog, JE
Muenter, MD
[J]. MOVEMENT DISORDERS, 2001, 16 (03) : 448 - 458
[3] Ahlskog JE, 1999, MOVEMENT DISORD, V14, P940, DOI 10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO
[4] 2-Y
[5] AHLSKOG JE, 2002, JAMA-J AM MED ASSOC, V288, P310
[6] Albin RL, 2002, JAMA-J AM MED ASSOC, V288, P311
[7] ALBIN RL, 2002, NEUROLOGY
[8] PERMANENT HUMAN PARKINSONISM DUE TO 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) - 7 CASES
BALLARD, PA
TETRUD, JW
LANGSTON, JW
[J]. NEUROLOGY, 1985, 35 (07) : 949 - 956
[9] Chase TN, 2000, ANN NEUROL, V47, pS122
[10] Medical management of Parkinson's disease
Clarke, CE
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 72 : I22 - I27

← 1 2 3 4 5 →